Filled for bankruptcy in March 2022
ODT - Odonate Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
ODT price evolution
ODT
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $95.74 | $110.84 | $133.87 | $157.98 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $99.58 | $112.07 | $136.1 | $159.87 |
| Long term investments | ||||
| Property, plant & equipment | $5.42 | $5.74 | $6.01 | $6.3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.19 | $6.5 | $6.78 | $8.01 |
| Total investments | ||||
| Total assets | $105.77 | $118.57 | $142.88 | $167.89 |
| Current liabilities | ||||
| Accounts payable | $11.66 | $13.12 | $15.25 | $14.17 |
| Deferred revenue | ||||
| Short long term debt | $0.74 | $0.73 | $0.71 | $0.66 |
| Total current liabilities | $30.3 | $29.65 | $33.09 | $27.07 |
| Long term debt | $4.11 | $4.3 | $4.48 | $4.67 |
| Total noncurrent liabilities | $4.11 | $4.3 | $4.48 | $4.67 |
| Total debt | $4.85 | $5.03 | $5.2 | $5.33 |
| Total liabilities | $34.4 | $33.95 | $37.58 | $31.74 |
| Shareholders' equity | ||||
| Retained earnings | -$436.21 | -$422.21 | -$400.19 | -$366.43 |
| Other shareholder equity | ||||
| Total shareholder equity | $71.37 | $84.63 | $105.3 | $136.15 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $157.98 | $181.17 | $139.3 | $198.1 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $159.87 | $183.93 | $139.8 | $202.95 |
| Long term investments | ||||
| Property, plant & equipment | $6.3 | $3.24 | $1.9 | $0.17 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8.01 | $4.9 | $2.87 | $0.55 |
| Total investments | ||||
| Total assets | $167.89 | $188.83 | $142.67 | $203.49 |
| Current liabilities | ||||
| Accounts payable | $14.17 | $15.58 | $10.78 | $4.3 |
| Deferred revenue | $0.46 | |||
| Short long term debt | $0.66 | $0.32 | ||
| Total current liabilities | $27.07 | $24.78 | $18.21 | $7.51 |
| Long term debt | $4.67 | $1.75 | ||
| Total noncurrent liabilities | $4.67 | $1.75 | $0.46 | |
| Total debt | $5.33 | $2.06 | ||
| Total liabilities | $31.74 | $26.53 | $18.67 | $7.51 |
| Shareholders' equity | ||||
| Retained earnings | -$366.43 | -$240.08 | -$128.25 | -$39.29 |
| Other shareholder equity | ||||
| Total shareholder equity | $136.15 | $162.3 | $124 | $195.98 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.87 | $18.63 | $30.93 | $30.07 |
| Selling, general & administrative | $11.15 | $3.43 | $2.89 | $2.36 |
| Total operating expenses | $14.02 | $22.05 | $33.82 | $32.43 |
| Operating income | -$14.02 | -$22.05 | -$33.82 | -$32.43 |
| Income from continuing operations | ||||
| EBIT | -$14 | -$22.02 | -$33.77 | -$32.29 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$14 | -$22.02 | -$33.77 | -$32.29 |
| Income (for common shares) | -$14 | -$22.02 | -$33.77 | -$32.29 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $117.04 | $104.03 | $79.95 | $27.9 |
| Selling, general & administrative | $10.39 | $10.9 | $10.82 | $4.84 |
| Total operating expenses | $127.43 | $114.93 | $90.76 | $32.74 |
| Operating income | -$127.43 | -$114.93 | -$90.76 | -$32.74 |
| Income from continuing operations | ||||
| EBIT | -$126.35 | -$111.83 | -$88.96 | -$32.74 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$126.35 | -$111.83 | -$88.96 | -$32.74 |
| Income (for common shares) | -$126.35 | -$111.83 | -$88.96 | -$32.74 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$14 | -$22.02 | -$33.77 | -$32.29 |
| Operating activities | ||||
| Depreciation | $0.26 | $0.26 | $0.27 | $0.27 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.74 | $1.34 | $2.1 | $2.31 |
| Total cash flows from operations | -$15.1 | -$23.03 | -$24.91 | -$31.5 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.02 | -$0.02 | |
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.02 | -$0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.82 | $0.52 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.82 | $0.52 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.1 | -$23.03 | -$24.11 | -$30.99 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$126.35 | -$111.83 | -$88.96 | -$32.74 |
| Operating activities | ||||
| Depreciation | $0.87 | $0.38 | $0.35 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.83 | $11.44 | $6.72 | $3.18 |
| Total cash flows from operations | -$113.13 | -$96.64 | -$67.09 | -$25.86 |
| Investing activities | ||||
| Capital expenditures | -$0.43 | -$0.17 | -$1.91 | -$0.08 |
| Investments | ||||
| Total cash flows from investing | -$0.43 | -$0.17 | -$1.91 | -$0.08 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $90.37 | $138.68 | $10.2 | $221.45 |
| Net borrowings | ||||
| Total cash flows from financing | $90.37 | $138.68 | $10.2 | $221.45 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$23.2 | $41.87 | -$58.8 | $195.51 |
News
|
60 Biggest Movers From Yesterday
Benzinga
11 Jan 2022
|
|
Biotech Bulls Tiptoe Into 2022 After One of the Worst Years Ever
Bloomberg via Yahoo Finance
17 Dec 2021
|
|
... GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate ...
WIBW Topeka
11 Dec 2021
|
|
Bitcoin Drops, Then Rebounds
TheStreet.com
8 Dec 2021
|
|
Stocks of the Week: Costco, AMC, Meta and More
TheStreet.com
6 Dec 2021
|
|
Donald Trump Media SPAC Digital World Acquisition In SEC Probe Linked To October Merger
TheStreet.com
6 Dec 2021
|
|
Tesla Stock Slides On Report of SEC Probe Into Whistleblower Complaints Linked To Solar Panel Risks
TheStreet.com
6 Dec 2021
|
|
54 Biggest Movers From Yesterday
Benzinga
19 Nov 2021
|
|
A Odonate Therapeutics, Inc. (NASDAQ:ODT) insider increased their holdings last year
Simply Wall St. via Yahoo Finance
25 Aug 2021
|
|
Do Institutions Own Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?
Simply Wall St. via Yahoo Finance
24 May 2021
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 38.49M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$101.00M |
| EBIT | -$102.07M |
| Net Income | -$102.07M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.85 |
| Cash/Share | 2.49 |
| EPS | -$2.65 |
|---|---|
| ROA | -76.30% |
| ROE | -102.72% |
| Debt/Equity | 0.23 |
|---|---|
| Net debt/EBITDA | 0.61 |
| Current ratio | 3.29 |
| Quick ratio | 3.29 |